Atlas Trials

Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma

Clinical trial NCT03727880 · COMPLETED

Trial details

NCT number
NCT03727880
Sponsor
Lei Zheng
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Resectable Pancreatic Ductal Adenocarcinoma (PDAC)Pancreatic Ductal Adenocarcinoma
Start date
2019-06-04
Primary completion
2025-01-15
Enrollment
28

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.